Lincoln Pharmaceuticals Limited — Important, 13-02-2025: Financial Result Updates

For the quarter ended December 2024, Lincoln Pharmaceuticals reported consolidated revenue from operations of ₹146.55 crore, a slight increase from ₹146.45 crore in the same quarter last year, reflecting a growth rate of 0.07%. The company's net profit stood at ₹20.77 crore, down 25.93% year-on-year from ₹28.04 crore. Consolidated EBITDA for Q3 FY25 was reported at ₹32.63 crore, a decrease of 19.79% compared to ₹40.68 crore in Q3 FY24.

Operational costs increased across various categories, with the cost of material consumed amounting to ₹50.16 crore and employee benefits expenses at ₹27.98 crore, indicating a strategic emphasis on maintaining a highly skilled workforce despite cost pressures. The overall operational efficiency was influenced by higher expenses across the board, which affected profitability.

On the balance sheet, the company demonstrated strong liquidity, with no term debt providing a solid foundation for future growth. The firm’s return ratios remain robust, and it continues to invest in research and innovation, boasting over 1,700 registered products.

Looking forward, Lincoln Pharmaceuticals aims for a revenue target of ₹750 crore by FY26, driven by geographic expansion and product diversification, particularly in lifestyle and chronic medication segments. With a strong growth strategy, complemented by recent milestones in product approvals and market entry, the outlook remains favorable despite current profit declines.

Given the current financial performance and growth ambitions, a hold position is advised, with keen observation of upcoming quarter results and strategic developments.